The invention provides for novel treatments of lysosomal storage diseases, in particular of Neuronal Ceroid Lipofuscinosis (NCL) or synucleinopathy or a disease characterized by block of autophagic flow. The treatment comprises administration of human pro-Cathepsin, in particular human pro-Cathpsin D, B or L to patients in need thereof.

The invention relates a method for producing a stable recombinant protein, comprising growing a non-naturally occurring host cell in a culture medium to produce a recombinant protein, and making a composition comprising the recombinant protein and a polysorbate. The production of endogenous lipoprotein lipase by the host cell is reduced. The endogenous lipoprotein lipase is present in the composition in a small amount, and is capable of degrading the polysorbate. The invention also relates to the relevant host cells and compositions, and preparation thereof.

This invention relates to the use of the Aspergillus niger aspergilloglutamic peptidase in a feed composition containing cereals, pulses, oilseeds, and/or tubers to improve animal performance, reduce nitrogen excretion and/or reduce intestinal inflammation. Furthermore, the present invention relates to a feed composition or a feed additive comprising the Aspergillus niger aspergilloglutamic peptidase. The present invention relates to the discovery that the Aspergillus niger aspergilloglutamic peptidase is capable of efficiently hydrolyzing alpha-amylase/trypsin inhibitors that are present in wheat, barley and related cereal species, as well as hydrolyzing trypsin inhibitors that are present in pulses, oilseeds, and tubers. Furthermore, the present invention relates to a method of improving animal performance comprising improving feed conversion ratio, and/or improving daily weight gain, and/or reducing intestinal inflammation, and/or reducing nitrogen excretion in an animal fed a feed stuff containing alpha-amylase and/or trypsin inhibitors, comprising orally administering a sufficient amount of the Aspergillus niger aspergilloglutamic peptidase. It also relates to the pretreatment of feedstuff with the Aspergillus niger aspergilloglutamic peptidase.

Provided herein is an isolated decelluarized amniotic membrane (DCM) and methods for using same therapeutically in vivo and in vitro. In one aspect, the isolated DCM is further processed, freezing, freeze drying, lyophilization micronized into powder or treatment with pepsin to create a hydrogel.

Novel fungal enzyme compositions, and more particularly, enzyme mixtures comprising a plurality of fungal enzymes (e.g., from Aspergillus and Candida) are provided. The disclosure further relates to dietary supplements, foods and beverages containing these enzyme mixtures, and methods of making and using the same.

The invention relates a method for producing a stable recombinant protein, comprising growing a non-naturally occurring host cell in a culture medium to produce a recombinant protein, and making a composition comprising the recombinant protein and a polysorbate. The production of endogenous lipoprotein lipase by the host cell is reduced. The endogenous lipoprotein lipase is present in the composition in a small amount, and is capable of degrading the polysorbate. The invention also relates to the relevant host cells and compositions, and preparation thereof.

Disclosed herein is a therapeutic intervention to prevent, reduce, or treat hemodialysis-associated skeletal muscle cramps by administering All receptor agonists or other pharmacologic agents that augment homeostatic responses to hemodialysis while preventing derecruitment of skeletal muscle capillaries.

Provided herein are methods and compositions for cardiac therapy. Such compositions include extracellular-matrix (ECM)-based products that can be used to support tissue repair. The compositions can be used for various purposes. In some cases, they can be introduced into a subject in order to preserve and/or repair damaged heart tissue.

Provided herein are methods and compositions for cardiac therapy. Such compositions include extracellular-matrix (ECM)-based products that can be used to support tissue repair. The compositions can be used for various purposes. In some cases, they can be introduced into a subject in order to preserve and/or repair damaged heart tissue.

Described herein are methods of identifying a mammal having a neurological disease or disorder, such as AD or MCI, or at risk for developing a neurological disease or disorder, such as AD or MCI. Provided herein are also methods of monitoring the progression of a neurological disease or disorder in a patient or monitoring the effectiveness of therapeutic agent or treatment of a patient having a neurological disease or disorder.